Across TCGA pan-cancer cohorts, GJB4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated GJB4 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GJB4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GJB4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
HNSC, BLCA, and OV are the cancer types where GJB4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.